Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans

Retina

Volumn 31, Issue 9, 2011, Pages 1877-1884

  Meyer, Carsten H ^a   Krohne, Tim U ^a,b   Holz, Frank G ^a  

^a UNIVERSITY OF BONN   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

anterior chamber concentration; double dosing; globe size; half time; intravitreal injection; unbound bevacizumab

Indexed keywords

BEVACIZUMAB;

ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; ASPIRATION; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE AXIS LENGTH; HUMAN; HUMAN TISSUE; INTERVENTION STUDY; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PHACOEMULSIFICATION; PROSPECTIVE STUDY; RETINA MACULA EDEMA; SINGLE DRUG DOSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CATARACT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCEIN ANGIOGRAPHY; HALF-LIFE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MIDDLE AGED; PHACOEMULSIFICATION; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053371459     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318217373c     Document Type: Article

References (36)

1. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
2. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
3. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina 2007;27:1196-1200.
4. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053.
5. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623-632.
6. Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest 1995;72:615-618.
7. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26: 257-261.
8. Feiner L, Barr EE, Shui YB, et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882-888.
9. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
10. Bashshur ZF, Bazarbachi A, Schakal A, et al; Intravitreal bevacizumab Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
11. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
12. Wu L, Arevalo JF, Roca JA, et al; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219.
13. Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: Results of the Pan American Collaborative Retina Study Group at 24 months. Retina 2009;29:1396-1403.
14. Wu L, Arevalo JF, Berrocal MH, et al. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: Results of the Pan-American Collaborative Retina Study Group at 24 months. Retina 2010;30:1002-1011.
15. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 2007;114: 743-750.
16. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
17. Arevalo JF, Sanchez JG, Fromow-Guerra J, et al; Pan- American Collaborative Retina Study Group (PACORES). Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009;247:735-743.
18. Lam DS, Lai TY, Lee VY, et al. Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina 2009;29:292-299.
19. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNVassociated with AMD. Retina 2009;29:319-324.
20. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: Results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28:1387-1394.
21. Wu L, Arevalo JF, Maia M, et al; Pan-American Collaborative Retina Study Group (PACORES). Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: Results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol 2009;53:125-130.
22. Geitzenauer W, Michels S, Prager F, et al. Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: Twenty-four week results of an uncontrolled, prospective cohort study. Retina 2008;28: 1375-1386.
23. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009;116:2158-2164.
24. Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006;26:871-876.
25. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-512.
26. Meyer CH, Krohne TU, Holz FG. The concentration of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol 2011. Epub ahead of print.
27. Sakurai K, Akiyama H, Shimoda Y, et al. Effect of intravitreal injection of high-hose bevacizumab in monkey eyes. Invest Ophthalmol Vis Sci 2009;50:4905-4916.
28. Helb HM, Charbel Issa P, Fleckenstein M, et al. Clinical evaluation of simultaneous confocal scanning laser ophthal- moscopy imaging combined with high-resolution, spectraldomain optical coherence tomography. Acta Ophthalmol 2011. Epub ahead of print.
29. Meyer CH, Helb HM, Holz FG. A computer-based documentation and data management system of clinically relevant parameters during repeated antivascular endothelial growth factor or steroid injections. Retina 2010;30:369-377.
30. Liu Z, Brinkmann CK, Rodrigues EB, et al. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0 cc syringe. Acta Ophthalmol 2011. Epub ahead of print.
31. Rodrigues EB, Grumann A, Shiroma H, et al. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. Am J Ophthalmol 2007;143:1035-1037.
32. Teichmann KD. Intravitreal injections: Does globe size matter? J Cat Ref Surg 2002;28:1886-1889.
33. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114: 855-859.
34. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009 50: 4807-4813.
35. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010;51:1606-1608.
36. Zhu Q, Ziemssen F, Henke-Fahle S, et al; Tübingen Bevacizumab Study Group, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115:1750-1755.